We are live on ! Find out more
NXTC icon

NextCure

83 hedge funds and large institutions have $158M invested in NextCure in 2020 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 22 increasing their positions, 29 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

87% more call options, than puts

Call options by funds: $2.59M | Put options by funds: $1.38M

67% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 12

11% more funds holding

Funds holding: 7583 (+8)

1% more capital invested

Capital invested by funds: $156M → $158M (+$2.1M)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

1.13% less ownership

Funds ownership: 5.52%4.4% (-1.1%)

24% less repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 29

Holders
83
Holders Change
+8
Holders Change %
+10.67%
% of All Funds
1.47%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
20
Increased
22
Reduced
29
Closed
12
Calls
$2.59M
Puts
$1.38M
Net Calls
+$1.21M
Net Calls Change
+$578K

NXTC Hedge Fund Activity: Q4 2020 in Review

83 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in NextCure (NXTC) for Q4 2020, worth a combined $158M — up 1.3% from $156M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new NXTC positions and 12 closed out — a net gain of 8 holders — while 22 added to existing stakes and 29 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $12M. The largest seller was Sofinnova Investments, exiting entirely with an estimated $23.5M sold.

  • 83 institutional investors held NextCure (NXTC) as of Q4 2020, up from 75 in Q3 2020.
  • Funds reported $158M of NextCure stock for Q4 2020, up 1.3% quarter-over-quarter.
  • 20 funds opened new NextCure positions in Q4 2020 and 12 closed out, a net change of +8 holders.
  • The largest NextCure buyer in Q4 2020 was Morgan Stanley, an estimated $12M added.
  • The largest NextCure seller in Q4 2020 was Sofinnova Investments, an estimated $23.5M sold.

Based on aggregated 13F filings for Q4 2020.